Skip to Content
Morningstar
Get 14 Days Free

Genfit SA

GNFTF Morningstar Rating
Rating as of

Related

Stock Strategist
Intercept Looks to Be First in Lucrative Market
But the pipeline of competing drugs is full, so we don’t see a moat for the biotech.
Anna Baran
Stock Strategist
Concerns About Allergan's Health Are Overblown
The stock price implies the worst-case scenario for this wide-moat company.
Michael Waterhouse
Stock Strategist
Big Opportunity in Liver Treatment for Intercept Pharmaceuticals
The firm's key program for treating NASH is well positioned, but the space is becoming increasingly crowded.
Kelsey Tsai